Burden Christy, Merriel Abi, Bakhbakhi Danya, Heazell Alexander, Siassakos Dimitrios
BJOG. 2025 Jan;132(1):e1-e41. doi: 10.1111/1471-0528.17844. Epub 2024 Oct 28.
A combination of mifepristone and a prostaglandin preparation should usually be recommended as the first-line intervention for induction of labour (Grade B). A single 200 milligram dose of mifepristone is appropriate for this indication, followed by: 24-24 weeks of gestation - 400 micrograms buccal/sublingual/vaginal/oral of misoprostol every 3 hours; 25-27 weeks of gestation - 200 micrograms buccal/sublingual/vaginal/oral of misoprostol every 4 hours; from 28 weeks of gestation - 25-50 micrograms vaginal every 4 hours, or 50-100 micrograms oral every 2 hours [Grade C]. There is insufficient evidence available to recommend a specific regimen of misoprostol for use at more than 28 weeks of gestation in women who have had a previous caesarean birth or transmural uterine scar [Grade D]. Women with more than two lower segment caesarean births or atypical scars should be advised that the safety of induction of labour is unknown [Grade D]. Staff should be educated in discussing mode of birth with bereaved parents. Vaginal birth is recommended for most women, but caesarean birth will need to be considered for some [Grade D]. A detailed informed discussion should be undertaken with parents of both physical and psychological aspects of a vaginal birth versus a caesarean birth [Grade C]. Parents should be cared for in an environment that provides adequate safety according to individual clinical circumstance, while meeting their needs to grieve and feel supported in doing so (GPP). Clinical and laboratory tests should be recommended to assess maternal wellbeing (including coagulopathy) and to determine the cause of fetal death, the chance of recurrence and possible means of avoiding future pregnancy complications [Grade D]. Parents should be advised that with full investigation (including postmortem and placental histology) a possible or probable cause can be found in up to three-quarters of late intrauterine fetal deaths [Grade B]. All parents should be offered cytogenetic testing of their baby, which should be performed after written consent is given (GPP). Parents should be advised that postmortem examination can provide information that can sometimes be crucial to the management of future pregnancy [Grade B].
米非司酮与前列腺素制剂联合使用通常应作为引产的一线干预措施(B级)。针对此适应证,单次给予200毫克米非司酮即可,随后:妊娠24 - 24周,每3小时口服/舌下含服/阴道给药/口服米索前列醇400微克;妊娠25 - 27周,每4小时口服/舌下含服/阴道给药/口服米索前列醇200微克;妊娠28周及以后,每4小时阴道给药米索前列醇25 - 50微克,或每2小时口服50 - 100微克[C级]。对于既往有剖宫产或子宫全层瘢痕的妇女,在妊娠28周以上使用米索前列醇的具体方案,目前尚无足够证据可供推荐[D级]。有两次以上下段剖宫产史或非典型瘢痕的妇女,应告知其引产安全性未知[D级]。工作人员应接受培训,以便与失去孩子的父母讨论分娩方式。大多数妇女建议经阴道分娩,但部分妇女需考虑剖宫产[D级]。应与父母就阴道分娩与剖宫产的身体和心理方面进行详细的知情讨论[C级]。应根据个体临床情况,在为父母提供充分安全保障的环境中给予照料,同时满足他们悲伤的需求并给予支持(良好临床实践)。应建议进行临床和实验室检查,以评估母亲的健康状况(包括凝血功能障碍),确定胎儿死亡原因、复发几率以及避免未来妊娠并发症的可能方法[D级]。应告知父母,经过全面检查(包括尸检和胎盘组织学检查),在多达四分之三的晚期宫内胎儿死亡病例中可找到可能或很可能的死因[B级]。应向所有父母提供对其婴儿进行细胞遗传学检测的服务,检测应在获得书面同意后进行(良好临床实践)。应告知父母,尸检可提供有时对未来妊娠管理至关重要的信息[B级]。